logo
    Docs
 

Target: ERBB2


Research on the Target ERBB2

1. Target Summary:

ERBB2, also known as HER2 (Human Epidermal Growth Factor Receptor 2), is a member of the epidermal growth factor receptor (EGFR) family. It plays a crucial role in cell growth, differentiation, and survival. Overexpression or amplification of ERBB2 is associated with aggressive forms of breast cancer and other malignancies, making it a significant target for therapeutic intervention.

2. Mechanism:

ERBB2 functions as a receptor tyrosine kinase that, upon ligand binding, dimerizes with other members of the EGFR family, leading to autophosphorylation and activation of downstream signaling pathways. These pathways include the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, which promote cell proliferation, survival, and migration.
  • Trastuzumab: This monoclonal antibody binds to the extracellular domain of HER2, inhibiting its signaling and promoting antibody-dependent cellular cytotoxicity (ADCC) (Barok M et al., 2014).
  • Trastuzumab Emtansine (T-DM1): This antibody-drug conjugate combines trastuzumab with a cytotoxic agent (DM1). It targets HER2-positive cells, leading to internalization of the drug and subsequent cell death through microtubule disruption (Hunter FW et al., 2020).
  • Trastuzumab Deruxtecan (T-DXd): Another antibody-drug conjugate that delivers a topoisomerase I inhibitor to HER2-positive cells, showing efficacy even in cases with low HER2 expression (Goto K et al., 2023).

3. Approved Drugs:

  • Trastuzumab (Herceptin): Approved for HER2-positive breast cancer.
  • Trastuzumab Emtansine (T-DM1, Kadcyla): Approved for metastatic HER2-positive breast cancer after prior treatment with trastuzumab and a taxane.
  • Trastuzumab Deruxtecan (Enhertu): Approved for HER2-positive breast cancer and gastric cancer.
  • Neratinib: An oral tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive breast cancer.
  • Tucatinib: Approved for use in combination with trastuzumab and capecitabine for HER2-positive metastatic breast cancer.

4. Hypotheses:

  • Hypothesis 1: ERBB2 overexpression correlates with poor prognosis in breast cancer patients, leading to the hypothesis that targeting ERBB2 can improve survival outcomes.
  • Hypothesis 2: Resistance mechanisms to HER2-targeted therapies may vary significantly across different cancer types, suggesting the need for personalized treatment approaches.
  • Hypothesis 3: Combining HER2-targeted therapies with immunotherapy may enhance treatment efficacy and overcome resistance mechanisms.

5. Validation:

  • Studies have shown that HER2-positive breast cancer patients treated with trastuzumab have improved survival rates compared to those who do not receive targeted therapy (Barok M et al., 2014).
  • Clinical trials have validated the efficacy of T-DM1 and T-DXd in patients who have progressed on prior HER2-targeted therapies, demonstrating that these agents can overcome some resistance mechanisms (Hunter FW et al., 2020; Goto K et al., 2023).
  • The FDA approval of multiple HER2-targeted therapies based on clinical trial data supports the validation of ERBB2 as a therapeutic target.

6. Clinical Trials:

  • Ongoing clinical trials are investigating the efficacy of novel HER2-targeted therapies in various cancers, including colorectal and gastric cancers (Robinson HR et al., 2024).
  • Trials are also exploring combination therapies involving HER2-targeted agents and immunotherapies to enhance treatment outcomes.

7. Involved Pathways:

  • PI3K/AKT/mTOR Pathway: Promotes cell survival and growth.
  • RAS/RAF/MEK/ERK Pathway: Involved in cell proliferation and differentiation.
  • ADCC Mechanism: Mediated by immune cells targeting HER2-positive cells.

8. Associated Genes:

  • ERBB2: The gene encoding the HER2 protein.
  • PIK3CA: Often mutated in HER2-positive cancers, affecting the PI3K pathway.
  • KRAS and NRAS: Mutations in these genes can influence the effectiveness of HER2-targeted therapies.

9. Target Expression:

  • ERBB2 is overexpressed in approximately 20-30% of breast cancers and is also found in other malignancies, including gastric and colorectal cancers. Testing for ERBB2 expression is critical for determining eligibility for HER2-targeted therapies.

10. Additional Context:

The landscape of HER2-targeted therapies is rapidly evolving, with ongoing research aimed at understanding resistance mechanisms and developing novel agents. The introduction of antibody-drug conjugates has expanded treatment options for patients with low HER2 expression, highlighting the importance of precise biomarker testing in clinical practice.

11. References:

  • Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):R30. PMID: 24887180.
  • Goto K, Goto Y, Kubo T. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol. 2023;41(31):3463-3473. PMID: 37694347.
  • Hunter FW, Barker HR, Lipert B. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):703-712. PMID: 31839676.
  • Robinson HR, Messersmith WA, Lentz RW. HER2-Positive Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2024;25(5):1-12. PMID: 38539034.